Activity of posaconazole in the treatment of central nervous system fungal infections. - Wikidata - wikimedia - TriplyDB

Activity of posaconazole in the treatment of central nervous system fungal infections.

Activity of posaconazole in the treatment of central nervous system fungal infections.

http://www.wikidata.org/entity/Q36246196

about

Melanized fungi in human disease Histoplasmosis: a clinical and laboratory update Integrated therapy for HIV and cryptococcosis Posaconazole: an oral triazole with an extended spectrum of activity Treatment of cryptococcosis in the setting of HIV coinfection.Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Antifungal clinical trials and guidelines: what we know and do not know Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Drug strategies targeting CYP51 in neglected tropical diseases Histoplasmosis Masquerading as a Rheumatoid Nodule in an Immunocompromised Host: A Case Report.Detection of posaconazole by surface-assisted laser desorption/ionization mass spectrometry with dispersive liquid-liquid microextraction.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.Posaconazole: a new broad-spectrum antifungal agent.Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Posaconazole in the management of refractory invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Epidemiology and management of cryptococcal meningitis: developments and challenges.Central nervous system infections by members of the Pseudallescheria boydii species complex in healthy and immunocompromised hosts: epidemiology, clinical characteristics and outcome.Antifungal agents--clinical pharmacokinetics and drug interactions.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Cryptococcosis in solid organ transplant recipients: current state of the science New and investigational triazole agents for the treatment of invasive fungal infections.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Pharmacologic and clinical evaluation of posaconazole.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Invasive aspergillosis in children with hematological malignancies.Posaconazole: when and how? The clinician's view.New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Central nervous system fungal infection in a young male with a history of intravenous drug abuse and hepatitis C.Posaconazole: a next-generation triazole antifungal.Fungal brain abscess caused by "Black Mold" (Cladophialophora bantiana) - A case report of successful treatment with an emphasis on how fungal brain abscess may be different from bacterial brain abscess.

P2860

Q24633163-E18AAC86-6A93-42C5-A8DD-BEAD78A702F1 Q24675642-9C6B4A90-88E3-4E83-A1DF-A2C5572C1721 Q28077707-141E6B53-2592-4120-87F5-65D458C23CAC Q28291282-0E48AC9B-4AB2-4057-A878-DE2A41EF6750 Q30366117-B40E86C6-D0B3-45FC-BC77-3D27C8EF26CA Q31033645-660F0F29-11B4-4F67-86F6-F2E1B9DDFD00 Q33650105-D9EC993C-3E9A-4297-B512-16EE38416157 Q34020746-6484CA62-F05F-485B-ABED-36A6C1F99613 Q34212799-B98DD1EE-DF25-4340-AF9B-D92ADF9A20B1 Q34400255-9DAD777E-789E-4184-972E-0FA8493B4FDF Q34433129-7E836F09-7560-4850-89A6-CEEA4273AB43 Q34498982-0514F403-5839-4134-B61B-1799DA95B59C Q34532546-02A97C36-076B-4FA1-A8C8-D238FE2A1B12 Q34622554-A6763536-5221-498F-8D0E-37305CBF0BEF Q34910933-A0EB2EC3-A831-4958-ACF7-94B833FC6CEC Q35538500-CBC661A1-AF42-49AF-87ED-F66C2BECFFAD Q36597431-CB4D4146-CAD8-401D-8CD2-47A65693B275 Q36825717-EA64F252-BE03-4899-A9A1-85553836344B Q36828159-ACE6A9F7-A93E-4ACF-A8D5-C2993E7DC0B5 Q37020761-39E6B420-35DF-4F6D-8B3A-03FB6016F86C Q37041199-DA823CB7-C8BE-42C9-9EC2-B85B97F6ECBB Q37052755-A6122616-F137-40BD-87D0-E5E94871E5A7 Q37055215-F5B5729A-4710-4859-96AC-E4D0E6B498B0 Q37096795-1A0BD3CD-15C5-405F-836A-DB9E3F05C5E6 Q37098995-3FD73110-02EF-49A3-8699-A1232240EEAC Q37106636-BFD9D388-78AA-4D8F-9F64-0EEC0FCC7CDB Q37159568-984AD3E9-4245-4EC5-BF5A-01AA5C6E14E3 Q37180338-DC801B5A-02AC-4FC5-BD50-8ABE792C1BCC Q37226750-F5F4D835-4EBE-410C-9EF6-CD3AB2E01C0D Q37364295-5C4FEDB7-C3E1-4171-96C7-5868BE784DC4 Q37404840-691C6781-00DE-47C9-9EB6-8CC9D4AA0CF9 Q37445943-8C3222BC-EFFB-48B7-8092-283B74250594 Q37813420-47F61532-0C99-4AB8-890D-F3DFF775525F Q37854719-A45F55AA-94A9-416C-8207-B19CA3D74DA8 Q37901534-BCBC61D1-0E3A-4DDE-A369-D489A7586F28 Q38024052-987FA7AB-09EF-496B-888B-2E811C6BB1EF Q38284461-7C977BD9-67BD-429B-AE2F-157511335F6F Q40084864-2F44F384-1729-4614-BCA1-C490B8B36DF1 Q40188974-77E998D0-5F09-4309-8937-A5F7E9805F44 Q40222976-18B645FD-281B-4D48-9221-700A0318C2A7

P2860

Activity of posaconazole in the treatment of central nervous system fungal infections.

http://www.wikidata.org/entity/Q36246196

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Activity of posaconazole in the treatment of central nervous system fungal infections.

@ast

Activity of posaconazole in the treatment of central nervous system fungal infections.

@en

type

label

Activity of posaconazole in the treatment of central nervous system fungal infections.

@ast

Activity of posaconazole in the treatment of central nervous system fungal infections.

@en

prefLabel

Activity of posaconazole in the treatment of central nervous system fungal infections.

@ast

Activity of posaconazole in the treatment of central nervous system fungal infections.

@en

P1433

Q36246196-F6D04733-A3A0-4682-B1C4-7C22900FB361

P1476

Q36246196-C76A0E91-8017-439B-B0BE-483D310C029C

P2093

Q36246196-01170A14-0C00-449C-A482-67EE6F9E71FF

Q36246196-205F1D78-B802-4FD0-B6E2-9F759C079CA4

Q36246196-2129424C-AC5B-4D83-B6B9-C75B050920D9

Q36246196-73AFFAE3-57B4-4A9A-82A2-5042A1AAF76A

Q36246196-8413FBD1-C021-47B5-A890-C1CDF3AD80F3

Q36246196-ADA2294B-A088-40A1-933A-9FCDA3034F7A

Q36246196-E2C7F906-FCEE-4BE8-9AF0-A55AD1BC6560

Q36246196-E9FCB7DB-59BA-4277-AB8D-10DF919AFC01

P2860

Q36246196-040B7806-F0CA-4D96-8200-4DAD32D980D2

Q36246196-0DE4D270-F9FF-4322-9D59-8B831DA270C8

Q36246196-0FB59788-E79F-4942-908F-8ADF1B693A3F

Q36246196-204D92A6-56A5-45A7-B1AB-86FAD2AE00DD

Q36246196-37169C46-62FD-40CB-A950-E2FEAAD6BB62

Q36246196-44730161-100E-4F06-80E4-CA68115C9773

Q36246196-520709F0-FAB6-4788-9019-031BED457E36

Q36246196-52E9128A-2C01-458D-8A72-631574FCE0BB

Q36246196-5A54ED51-9472-44A0-83EF-B7FF2D5DE9A1

Q36246196-5B96268E-08FD-45C8-A83B-3A0FA31A656E

P304

Q36246196-DE1C27B3-F666-4432-80BF-3F099AE9D734

P31

Q36246196-3AF260A6-C66F-4824-8E70-2B44AA5490C2

P356

Q36246196-650CA0B8-E3B6-4388-999C-3B18521268A8

P407

Q36246196-8B1F6FB6-0175-4D43-B8B5-AB0264EAC765

P433

Q36246196-455D007E-98D3-418F-82EA-AFCF54DC0A5E

P478

Q36246196-16D82047-1ED0-4241-9F23-3EBF84F1B1B9

P577

Q36246196-6DB05468-06C5-43CE-8227-663957E26736

P5875

Q36246196-F8E18922-0599-42E9-9B3F-243F12D48173

P698

Q36246196-2ECF3F45-4513-4480-A9FD-AE5A9216B3EF

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Activity of posaconazole in the treatment of central nervous system fungal infections.

@en

P2093

Beatriz Bustamante

http://www.w3.org/2001/XMLSchema#string

Catherine J Hardalo

http://www.w3.org/2001/XMLSchema#string

John R Graybill

http://www.w3.org/2001/XMLSchema#string

Peter Pappas

http://www.w3.org/2001/XMLSchema#string

Punnee Pitisuttithum

http://www.w3.org/2001/XMLSchema#string

Ricardo Negroni

http://www.w3.org/2001/XMLSchema#string

Roberta S Hare

http://www.w3.org/2001/XMLSchema#string

Stanley Chapman

http://www.w3.org/2001/XMLSchema#string

P2860

Zygomycetes in human disease

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

In vitro activities of four novel triazoles against Scedosporium spp

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

In vitro and in vivo activities of posaconazole against Coccidioides immitis.

Emerging pathogens.

Primary central nervous system phaeohyphomycosis: a review of 101 cases.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

P304

745-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKI288

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7624735

http://www.w3.org/2001/XMLSchema#string

P698

16135526

http://www.w3.org/2001/XMLSchema#string